Allos, Spectrum Pharmaceuticals deal

Spectrum extended to 5 p.m. EDT on Aug. 20 from Aug. 6 its tender offer to acquire cancer company Allos for $1.82 per share in cash. Spectrum said it extended the offer to "continue cooperating" with a May request from the U.S. Federal Trade Commission (FTC) requesting information under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 from both companies for more information on the acquisition. At Aug. 3, about 62.5 million shares, or about 58.4% of Allos' stock, were tendered (see BioCentury, April 9 & July 30). ...